Anzeige
Meldung des Tages: Goldchance mit Substanz: Warum dieses Projekt Investoren aufhorchen lässt

Dr Reddy's Laboratories Aktie News

Aktie
WKN:  659157 ISIN:  US2561352038 US-Symbol:  RDY Branche:  Pharmazeutika Land:  Indien
13,975 $
-0,03 $
-0,21%
11,847 € 19:55:54 Uhr
Depot/Watchlist
Marktkapitalisierung *
10,04 Mrd. €
Streubesitz
86,06%
KGV
-
Dividende
0,093 $
Dividendenrendite
0,80%
Index-Zuordnung
DBIX Deutsche Börse India EUR (Performance)

Dr Reddy's Laboratories News

25.08.25 - PR Newswire
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire
09.04.25 - wallstreetONLINE Redaktion
Handelskrieg: Trump plant nächsten Zollhammer: Medikamenten-Zölle! Pharma-Werte unter Druck
Trump plant Zölle auf Medikamente – indische Pharmawerte brechen ein. Die US-​Ankündigung sorgt für Turbulenzen an der Börse. Besonders Generika-​Hersteller stehen unter ...
27.03.25 - PR Newswire
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for ...
22.03.24 - wallstreetONLINE Redaktion
Incredible India: Gehört Indien die Zukunft? Aktien, ETFs und Fonds aus dem Land der Gegensätze
Der indische Markt entwickelt sich stärker als europäische und US-​Leitindizes. Erfahren Sie, welche Faktoren die Entwicklung begünstigen und welche Aktien, ETFs und Fonds zur ...
13.04.22 - wallstreetONLINE Redaktion
Rendite-Liste: Bernstein: Diese Indien-Aktien könnten um zehn Prozent und mehr steigen
Foto: Free-​Photos - pixabay.com Indische Aktien mit mehr als zehn Prozent Aufwärtspotenzial haben Bernstein-​Analysten gefunden. Eine hätte gar das Potential, um an die 40 ...
07.09.21 - PR Newswire
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-​Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other ...
03.06.21 - PR Newswire
Global Response Aid Reports Midyear Sales Results for COVID Drug
Global Response Aid Reports Midyear Sales Results for COVID Drug Reports sales of 11 million anti-​viral Avigan® tablets in first seven months PR Newswire
03.03.21 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY PR Newswire
02.02.21 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY PR Newswire
06.02.20 - PR Newswire
Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170
Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170 - Aurigene to fund and conduct a Phase 2b/3 randomized study of ...
20.07.19 - PR Newswire
Upsher-Smith Laboratories Completes Acquisition Of Two Treatments For Acute Migraine In Adults
Upsher-​Smith Laboratories Completes Acquisition Of Two Treatments For Acute Migraine In Adults Strategic Acquisition of Tosymra™ (sumatriptan) Nasal Spray and Zembrace® ...
13.06.19 - PR Newswire
Upsher-Smith Laboratories Enters Into Agreement To Acquire Tosymra™ (sumatriptan nasal spray) And Zembrace® SymTouch® (sumatriptan injection)
Upsher-​Smith Laboratories Enters Into Agreement To Acquire Tosymra™ (sumatriptan nasal spray) And Zembrace® SymTouch® (sumatriptan injection) Strategic Acquisition ...
01.05.19 - PR Newswire
URGENT: Monteverde & Associates PC Invites Dr. Reddy's Laboratories Ltd. Shareholders or Former Shareholders To Contact the Firm Immediately
URGENT: Monteverde & Associates PC Invites Dr. Reddy's Laboratories Ltd. Shareholders or Former Shareholders To Contact the Firm Immediately PR Newswire
15.06.18 - PR Newswire
Dr. Reddy's Laboratories announces USFDA final approval and launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market
Dr. Reddy's Laboratories announces USFDA final approval and launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market PR Newswire
21.03.18 - Aktienwelt360
3 Dinge, die die Investoren von Celgene nach dem Ozanimod-Debakel wissen möchten
Die Geschichte von Celgene (WKN:881244) könnte aus einem traurigen Country-​Song kommen. Das große Biotech-​Unternehmen hat in den vergangenen sechs Monaten mehr ...
18.10.17 - PR Newswire
EQUITY ALERT: Goldberg Law PC Announces a Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited
EQUITY ALERT: Goldberg Law PC Announces a Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited PR Newswire
13.10.17 - PR Newswire
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Dr. Reddy's Laboratories Ltd. - RDY
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Dr. Reddy's Laboratories Ltd. - RDY PR Newswire
11.10.17 - PR Newswire
DR. REDDY'S INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Dr. Reddy's Laboratories Limited To Contact The Firm
DR. REDDY'S INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Dr. Reddy's Laboratories Limited To Contact The Firm ...
22.09.17 - PR Newswire
DR. REDDY'S SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Dr. Reddy's Laboratories Ltd. - (RDY)
DR. REDDY'S SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Dr. ...
15.09.17 - PR Newswire
DR. REDDY'S SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Ag
DR. REDDY'S SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 ...

Newssuche

Videos

newspaper
10:20 Uhr +9,48%
Technical Trading: Pfund Short im Februar
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »